PMID

Data

Article Title

Organization

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Merck Research Laboratories

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Pfizer

Prediction of Thorough QT study results using action potential simulations based on ion channel screens.

University of Oxford

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

Astrazeneca

Ion channels as therapeutic targets: a drug discovery perspective.

Pfizer

Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor.

Vanderbilt University Medical Center

Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator.

Vanderbilt University Medical Center

N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy.

TBA

Current and novel approaches to the drug treatment of schizophrenia.

Merck Sharp and Dohme Research Laboratories

Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.

Abbott Laboratories

Design, synthesis and biological activity of pyrazolo[1,5-a]pyrimidin-7(4H)-ones as novel Kv7/KCNQ potassium channel activators.

Hebei Medical University

SAGE-718: A First-in-Class

Sage Therapeutics

Discovery of the First Orally Available, Selective K

Praxis Precision Medicines

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Sareum

Synthesis and activity of novel and selective I(Ks)-channel blockers.

Aventis Pharma Deutschland

Development of Chemical Entities Endowed with Potent Fast-Killing Properties against

Glaxosmithkline

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease.

TBA

The discovery and optimization of benzimidazoles as selective Na

Pfizer

Neuroactive Steroids. 2. 3?-Hydroxy-3?-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5?-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (?-Aminobutyric Acid)

Sage Therapeutics

Discovery of a Series of Indazole TRPA1 Antagonists.

Pfizer